Adding bevacizumab to chemotherapy for platinum-resistant ovarian cancer improves progression-free survival

Share :
Published: 2 Jun 2012
Views: 4008
Dr Eric Pujade-Lauraine - Université Paris Descartes, France

At a press conference during the ASCO 2012 Annual Meeting in Chicago, June 1st - June 4th, Dr Eric Pujade-Lauraine presented results from a phase III randomised trial that added bevacizumab to standard chemotherapy which doubled progression-free survival in women with platinum-resistant ovarian cancer.